SE509694C2 - Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter - Google Patents
Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salterInfo
- Publication number
- SE509694C2 SE509694C2 SE9102604A SE9102604A SE509694C2 SE 509694 C2 SE509694 C2 SE 509694C2 SE 9102604 A SE9102604 A SE 9102604A SE 9102604 A SE9102604 A SE 9102604A SE 509694 C2 SE509694 C2 SE 509694C2
- Authority
- SE
- Sweden
- Prior art keywords
- composition according
- methyl
- bismuth
- ranitidine
- salt
- Prior art date
Links
- 229960000620 ranitidine Drugs 0.000 title claims abstract description 13
- 229910052797 bismuth Inorganic materials 0.000 title claims abstract description 11
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 title claims abstract description 9
- -1 bismuth carboxylic acid salts Chemical class 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000011975 tartaric acid Substances 0.000 claims abstract description 3
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 39
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
- 159000000011 group IA salts Chemical class 0.000 claims description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 241001397173 Kali <angiosperm> Species 0.000 claims 1
- LUOYFQVUYMMTRC-UHFFFAOYSA-N bismuth(3+) Chemical compound [Bi+3].[Bi+3] LUOYFQVUYMMTRC-UHFFFAOYSA-N 0.000 claims 1
- XAUTYMZTJWXZHZ-UHFFFAOYSA-K bismuth;1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical group [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-UHFFFAOYSA-K 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 18
- 235000019359 magnesium stearate Nutrition 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 3
- 229960004696 ranitidine bismuth citrate Drugs 0.000 description 3
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909019875A GB9019875D0 (en) | 1990-09-11 | 1990-09-11 | Pharmaceutical compositions |
| NO920408A NO179694C (no) | 1990-09-11 | 1992-01-30 | Farmasöytiske preparater inneholdende ranitidinderivater |
| PCT/EP1992/000498 WO1993017679A1 (en) | 1990-09-11 | 1992-03-05 | Compositions containing ranitidine/bismuth carboxylates salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9102604D0 SE9102604D0 (sv) | 1991-09-10 |
| SE9102604L SE9102604L (sv) | 1992-03-12 |
| SE509694C2 true SE509694C2 (sv) | 1999-02-22 |
Family
ID=47884627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9102604A SE509694C2 (sv) | 1990-09-11 | 1991-09-10 | Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5456925A (ko) |
| EP (1) | EP0558779B1 (ko) |
| JP (1) | JPH0692849A (ko) |
| KR (1) | KR100196308B1 (ko) |
| AT (2) | AT405134B (ko) |
| AU (2) | AU640816B2 (ko) |
| BE (1) | BE1005115A5 (ko) |
| BG (1) | BG61931B1 (ko) |
| CA (1) | CA2050970C (ko) |
| CH (1) | CH683068A5 (ko) |
| CY (1) | CY1988A (ko) |
| DE (2) | DE4130061A1 (ko) |
| DK (1) | DK159191A (ko) |
| ES (1) | ES2072647T3 (ko) |
| FI (1) | FI944047A (ko) |
| FR (1) | FR2666508B1 (ko) |
| GB (2) | GB9019875D0 (ko) |
| HK (1) | HK60894A (ko) |
| HU (1) | HU211846A9 (ko) |
| IE (1) | IE65049B1 (ko) |
| IL (1) | IL99428A (ko) |
| IT (1) | IT1249696B (ko) |
| MX (1) | MX9101009A (ko) |
| NL (1) | NL194907C (ko) |
| NO (1) | NO179694C (ko) |
| NZ (1) | NZ239731A (ko) |
| OA (1) | OA10093A (ko) |
| RO (1) | RO112084B1 (ko) |
| RU (1) | RU2108097C1 (ko) |
| SE (1) | SE509694C2 (ko) |
| SK (1) | SK279591B6 (ko) |
| WO (1) | WO1993017679A1 (ko) |
| ZA (1) | ZA917176B (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9120131D0 (en) * | 1991-09-20 | 1991-11-06 | Glaxo Group Ltd | Medicaments |
| ES2130152T3 (es) * | 1991-12-06 | 1999-07-01 | Glaxo Group Ltd | Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto. |
| GB9127150D0 (en) * | 1991-12-20 | 1992-02-19 | Smithkline Beecham Plc | Novel treatment |
| DE69620582T2 (de) * | 1995-01-26 | 2002-11-07 | Nycomed Imaging As | Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden |
| GB9501560D0 (en) | 1995-01-26 | 1995-03-15 | Nycomed Imaging As | Contrast agents |
| RU2203048C2 (ru) * | 1998-08-18 | 2003-04-27 | Леонидов Николай Борисович | Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения |
| EP1104673A1 (en) * | 1999-11-30 | 2001-06-06 | Bayer Classics | A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition |
| KR100412290B1 (ko) * | 2001-11-27 | 2003-12-31 | 주식회사 동구제약 | 라니티딘 함유 현탁제 조성물 및 그의 제조방법 |
| US20060100271A1 (en) * | 2004-11-08 | 2006-05-11 | Keith Whitehead | Stabilized aqueous ranitidine compositions |
| US9629809B2 (en) | 2008-07-21 | 2017-04-25 | Si Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| JP5553830B2 (ja) * | 2008-07-21 | 2014-07-16 | アルベマール・コーポレーシヨン | 高含量イブプロフェンナトリウム顆粒、その調製、および非発泡性固体剤形を調製する際のその使用 |
| CN115697354A (zh) * | 2020-06-01 | 2023-02-03 | 香港大学 | 用于治疗sars-cov-2感染的组合物和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4608257A (en) * | 1984-01-03 | 1986-08-26 | Board Of Regents For Oklahoma State University | Composition and method for treating heat stress |
| GB8629781D0 (en) * | 1986-12-12 | 1987-01-21 | Glaxo Group Ltd | Pharmaceutical compositions |
| DE3874917T2 (de) * | 1987-03-09 | 1993-03-04 | Procter & Gamble | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. |
| DE3710462A1 (de) * | 1987-03-30 | 1988-10-13 | Heumann Pharma Gmbh & Co | Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes |
| FR2633181B1 (fr) * | 1988-06-24 | 1992-01-10 | Glaxo Lab Sa | Composition pharmaceutique a base de ranitidine et son procede de preparation |
| CH679582A5 (ko) * | 1988-07-18 | 1992-03-13 | Glaxo Group Ltd | |
| ES2040307T3 (es) * | 1988-10-08 | 1993-10-16 | Dr. R. Pfleger Chemische Fabrik Gmbh | Procedimiento para producir un preparado medicamentoso liquido que contiene bismuto. |
| AU641903B2 (en) * | 1988-10-26 | 1993-10-07 | Glaxo Group Limited | Carboxylic acid derivatives |
| US5013560A (en) * | 1989-03-17 | 1991-05-07 | The Procter & Gamble Company | Microbially-stable bismuth-containing liquid pharmaceutical suspensions |
| GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
-
1990
- 1990-09-11 GB GB909019875A patent/GB9019875D0/en active Pending
-
1991
- 1991-09-06 IL IL9942891A patent/IL99428A/en not_active IP Right Cessation
- 1991-09-09 CA CA002050970A patent/CA2050970C/en not_active Expired - Fee Related
- 1991-09-10 GB GB9119284A patent/GB2248185B/en not_active Expired - Fee Related
- 1991-09-10 AT AT0180191A patent/AT405134B/de not_active IP Right Cessation
- 1991-09-10 DK DK159191A patent/DK159191A/da not_active Application Discontinuation
- 1991-09-10 CH CH2655/91A patent/CH683068A5/fr not_active IP Right Cessation
- 1991-09-10 ZA ZA917176A patent/ZA917176B/xx unknown
- 1991-09-10 KR KR1019910015760A patent/KR100196308B1/ko not_active IP Right Cessation
- 1991-09-10 NL NL9101533A patent/NL194907C/nl not_active IP Right Cessation
- 1991-09-10 NZ NZ239731A patent/NZ239731A/en unknown
- 1991-09-10 IE IE319191A patent/IE65049B1/en not_active IP Right Cessation
- 1991-09-10 AU AU83757/91A patent/AU640816B2/en not_active Ceased
- 1991-09-10 SE SE9102604A patent/SE509694C2/sv not_active IP Right Cessation
- 1991-09-10 IT ITRM910673A patent/IT1249696B/it active IP Right Grant
- 1991-09-10 FR FR9111146A patent/FR2666508B1/fr not_active Expired - Fee Related
- 1991-09-10 DE DE4130061A patent/DE4130061A1/de not_active Withdrawn
- 1991-09-10 JP JP3230571A patent/JPH0692849A/ja active Pending
- 1991-09-10 BE BE9100841A patent/BE1005115A5/fr not_active IP Right Cessation
-
1992
- 1992-01-30 NO NO920408A patent/NO179694C/no not_active IP Right Cessation
- 1992-03-05 RU RU94040869A patent/RU2108097C1/ru active
- 1992-03-05 MX MX9101009A patent/MX9101009A/es unknown
- 1992-03-05 RO RO94-01459A patent/RO112084B1/ro unknown
- 1992-03-05 ES ES92103741T patent/ES2072647T3/es not_active Expired - Lifetime
- 1992-03-05 AU AU13347/92A patent/AU1334792A/en not_active Abandoned
- 1992-03-05 SK SK1060-94A patent/SK279591B6/sk unknown
- 1992-03-05 DE DE69202696T patent/DE69202696D1/de not_active Expired - Lifetime
- 1992-03-05 EP EP92103741A patent/EP0558779B1/en not_active Expired - Lifetime
- 1992-03-05 AT AT92103741T patent/ATE122883T1/de not_active IP Right Cessation
- 1992-03-05 WO PCT/EP1992/000498 patent/WO1993017679A1/en active IP Right Grant
-
1994
- 1994-03-22 US US08/215,658 patent/US5456925A/en not_active Expired - Lifetime
- 1994-06-23 HK HK60894A patent/HK60894A/xx not_active IP Right Cessation
- 1994-08-12 OA OA60553A patent/OA10093A/en unknown
- 1994-09-01 BG BG99021A patent/BG61931B1/bg unknown
- 1994-09-02 FI FI944047A patent/FI944047A/fi unknown
-
1995
- 1995-06-28 HU HU95P/P00511P patent/HU211846A9/hu unknown
-
1997
- 1997-09-05 CY CY198897A patent/CY1988A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2142790C1 (ru) | Фармацевтическая композиция, стабилизированная основным агентом | |
| US5529783A (en) | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan | |
| HU193434B (en) | Process for producing antibiotic compositions of retarde activity | |
| SE509694C2 (sv) | Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter | |
| US4370313A (en) | Nitrofurantoin dosage form | |
| US3865935A (en) | Tableting of erythromycin base | |
| CA2361843C (en) | Swallowable tablets with high content of n-acetylcysteine | |
| US3891755A (en) | Dosage formulation for erythromycin cetyl sulfate | |
| EP2117534B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
| KR920008161B1 (ko) | 오메프라졸 경구용 약제의 제조방법 | |
| JP2006328001A (ja) | 経口投与用製剤 | |
| HUT67577A (en) | Process for production of adsorbate comprising adjuvant-mixture and non-solid active agent using production of preparations | |
| HU217587B (hu) | Ranitidint és bizmut-karboxilát-komplexet, valamint bázisos sókat tartalmazó gyógyászati készítmények | |
| CN113679687A (zh) | 一种复合释药组合物、口崩片组合物和口崩制剂及其应用 | |
| RU2240112C1 (ru) | Лекарственная форма, обладающая бактериостатическим действием, и способ ее изготовления | |
| CZ209794A3 (en) | Pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |